tailieunhanh - Báo cáo y học: "Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosu"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. | Available online http content 8 3 R74 Research article Initial clinical trial of epratuzumab humanized anti-CD22 antibody for immunotherapy of systemic lupus erythematosus Thomas Dorner1 Joerg Kaufmann1 William A Wegener2 NickTeoh2 David M Goldenberg2 3 and Gerd R Burmester1 Department of Medicine Rheumatology and Clinical Immunology Charite Hospital Berlin Germany 2Immunomedics Inc. Morris Plains NJ USA 3Center for Molecular Medicine and Immunology Belleville NJ USA Corresponding author Thomas Dorner Received 2 Nov 2005 Revisions requested 4 Jan 2006 Revisions received 21 Mar 2006 Accepted 22 Mar 2006 Published 21 Apr 2006 Arthritis Research Therapy 2006 8 R74 doi ar1942 This article is online at http content 8 3 R74 2006 Dorner et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract B cells play an important role in the pathogenesis of systemic lupus erythematosus SLE so the safety and activity of anti-B cell immunotherapy with the humanized anti-CD22 antibody epratuzumab was evaluated in SLE patients. An open-label single-center study of 14 patients with moderately active SLE total British Isles Lupus Assessment Group BILAG score 6 to 12 was conducted. Patients received 360 mg m2 epratuzumab intravenously every 2 weeks for 4 doses with analgesic antihistamine premedication but no steroids prior to each dose. Evaluations at 6 10 18 and 32 weeks 6 months posttreatment follow-up included safety SLE activity BILAG score blood levels of epratuzumab B and T cells immunoglobulins and human anti-epratuzumab antibody HAHA titers. Total BILAG scores decreased by 50 in all 14 patients at some point during the study including 77 with

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.